Sydney Lupkin
WFAE
Washington, DC, United States
Contact Sydney
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Sydney:
5 things to know about the FDA's flawed approach to accelerated drug approvals
An NPR investigation found stalled confirmatory trials and lax enforcement are plaguing the FDA's accelerated approval of drugs for urgent medical needs. → Read More
5 things to know about the FDA's flawed approach to accelerated drug approvals
An NPR investigation found stalled confirmatory trials and lax enforcement are plaguing the FDA's accelerated approval of drugs for urgent medical needs. → Read More
Drugmakers are slow to prove medicines that got a fast track to market really work
Stalled confirmatory trials and lax enforcement plague the Food and Drug Administration's accelerated approval pathway for pharmaceuticals that target urgent medical needs. → Read More
Feds' contract with Pfizer for Paxlovid has some surprises
NPR has obtained the government's $5.3 billion contract for the first 10 million courses of Paxlovid, an antiviral pill for COVID-19. Here's what's in it. → Read More
The COVID antiviral drugs are here but they're scarce. Here's what to know
Paxlovid and molnupiravir have been authorized for emergency use to keep COVID-19 patients out of the hospital, but don't expect to be able to go to your usual pharmacy and get them. → Read More
Omicron boosters are in the works, but will they be needed?
Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus. → Read More
Omicron boosters are in the works, but will they be needed?
Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus. → Read More
Hormone Blocker Sticker Shock — Again — As Patients Lose Cheaper Drug Option
Kids who need a hormone-blocking drug to delay puberty have lost an off-label option. The nearly identical drug the company still sells costs eight times more. → Read More
Drugmaker drops cheaper version of drug, leaving patients stuck with pricier one
Kids who need hormone-blocking drugs to prevent premature puberty — or delay it if they're trans — have lost a more affordable option. The remaining nearly identical drug costs eight times more. → Read More
Fewer COVID Vaccine Doses Materialized Last Fall Than The U.S. Government Hoped
Manufacturers can expect to face unforeseen hurdles when they begin to mass-produce a brand new pharmaceutical product, and in a pandemic, there are bound to be supply chain problems as well. But in late 2020, Pfizer was delivering fewer doses than the government expected and then-federal officials told NPR they did not know why. → Read More
CDC Warns Against Off-Label Use Of COVID Vaccine
Using the COVID vaccine "off-label" — whether that's for booster shots or young children — may be tempting to some vaccine providers, but the CDC warns it could get them into trouble. → Read More
The U.S. Paid Billions To Get Enough COVID Vaccines Last Fall. What Went Wrong?
Immediately after the Food and Drug Administration authorized Pfizer's vaccine, the company delivered fewer doses than its government contract projected. Federal officials say they didn't know why. → Read More
The U.S. Paid Billions To Get Enough COVID Vaccines Last Fall. What Went Wrong?
Immediately after the Food and Drug Administration authorized Pfizer's vaccine, the company delivered fewer doses than its government contract projected. Federal officials say they didn't know why. → Read More
COVID Booster Shots Are Coming. Here's What You Need To Know
If all goes to plan, Americans who got Pfizer or Moderna shots can get a third dose eight months after their last jab. Here's why health officials think you'll need one. → Read More
Lawmakers Grill Vaccine Factory Executives About Manufacturing Mistakes
House subcommittee members questioned why Emergent BioSoultions awarded bonuses to executives despite quality problems than hindered production of Johnson & Johnson's COVID-19 vaccine. → Read More
Why There Will Be Fewer Johnson & Johnson COVID-19 Vaccines Next Week
A dip of 86% in doses to be distributed to states follows a surge that occurred after one of J&J's third party manufacturers was finally able to release a stockpile. → Read More
Operation Warp Speed's Slaoui Ousted From Medical Company Board Over Misconduct Claim
Moncef Slaoui, who helped lead Operation Warp Speed under the Trump administration, was removed from a medical device startup's board over allegations of sexual harassment. → Read More
Defense Production Act Speeds Up Vaccine Production
A 1950 law allows the government to award contracts that take priority over all others for national defense. During the pandemic, the law has been used to defend the country against the coronavirus. → Read More
Moderna And Pfizer On Track To Hit Vaccine Production Goals
Pfizer and Moderna each agreed to supply 100 million doses of COVID-19 vaccine to the U.S. by the end of March. With just under three weeks left, both companies have their work cut out for them. → Read More
Moderna And Pfizer On Track To Hit Vaccine Production Goals
President Biden's promise that there will be enough vaccines for every U.S. adult by the end of May has some Americans wondering if it's too good to be true. → Read More